Cerus Corp
CERS1.300USD
+0.030+2.36%
Market hours （ET）Quotes delayed by 15 min
248.45MMarket Cap
LossP/E TTM
More Details of Cerus Corp Company
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Company Info
Ticker SymbolCERS
Company nameCerus Corp
IPO dateJan 31, 1997
CEOMr. William M. (Obi) Greenman
Number of employees281
Security typeOrdinary Share
Fiscal year-endJan 31
Address1220 Concord Avenue
CityCONCORD
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94520
Phone19252886000
Websitehttps://www.cerus.com/
Ticker SymbolCERS
IPO dateJan 31, 1997
CEOMr. William M. (Obi) Greenman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--
Mr. Dean A. Gregory
Mr. Dean A. Gregory
Director
Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Richard J. Benjamin, Ph.D.
Dr. Richard J. Benjamin, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Timothy L. (Tim) Moore
Mr. Timothy L. (Tim) Moore
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
304.17K
+24.57%
Mr. Kevin Dennis Green, CPA
Mr. Kevin Dennis Green, CPA
Chief Financial Officer, Vice President - Finance
Chief Financial Officer, Vice President - Finance
289.70K
-64.05%
Ms. Ann Lucena
Ms. Ann Lucena
Independent Director
Independent Director
182.05K
+49.16%
Dr. Hua Shan, M.D., Ph.D.
Dr. Hua Shan, M.D., Ph.D.
Independent Director
Independent Director
131.10K
+84.39%
Mr. William M. (Obi) Greenman
Mr. William M. (Obi) Greenman
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Jami K. Nachtsheim ,
Jami K. Nachtsheim ,
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Product
43.24M
0.00%
By RegionUSD
Name
Revenue
Proportion
North America
30.60M
70.77%
Europe and Middle East and Africa
12.21M
28.24%
Other
427.00K
0.99%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
43.24M
0.00%
Shareholding Stats
Updated: Thu, May 22
Updated: Thu, May 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
10.12%
ARK Investment Management LLC
10.05%
BlackRock Institutional Trust Company, N.A.
6.77%
The Vanguard Group, Inc.
5.52%
Wasatch Global Investors Inc
4.35%
Other
63.19%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
10.12%
ARK Investment Management LLC
10.05%
BlackRock Institutional Trust Company, N.A.
6.77%
The Vanguard Group, Inc.
5.52%
Wasatch Global Investors Inc
4.35%
Other
63.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.51%
Hedge Fund
20.42%
Investment Advisor/Hedge Fund
20.22%
Individual Investor
4.69%
Research Firm
3.80%
Family Office
1.22%
Venture Capital
0.10%
Bank and Trust
0.09%
Pension Fund
0.07%
Other
19.86%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
330
149.69M
78.31%
-11.42M
2025Q1
349
154.49M
80.95%
-4.85M
2024Q4
362
150.65M
81.09%
-18.33M
2024Q3
373
152.20M
82.15%
-11.01M
2024Q2
387
150.50M
81.41%
-12.83M
2024Q1
386
146.19M
80.62%
-12.96M
2023Q4
385
141.79M
78.32%
-24.31M
2023Q3
382
146.35M
81.02%
-13.17M
2023Q2
384
145.73M
80.79%
-19.32M
2023Q1
387
151.80M
85.48%
-8.28M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
19.35M
10.12%
-126.25K
-0.65%
Mar 31, 2025
ARK Investment Management LLC
20.66M
10.81%
-159.61K
-0.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
12.94M
6.77%
+28.20K
+0.22%
Mar 31, 2025
The Vanguard Group, Inc.
10.55M
5.52%
+137.20K
+1.32%
Mar 31, 2025
Wasatch Global Investors Inc
8.32M
4.35%
--
--
Mar 31, 2025
Nikko Asset Management Co., Ltd.
6.19M
3.24%
-270.80K
-4.19%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.54M
2.38%
+87.67K
+1.97%
Mar 31, 2025
Senvest Management, LLC
4.41M
2.3%
-1.99M
-31.10%
Mar 31, 2025
State Street Global Advisors (US)
3.80M
1.99%
-8.14K
-0.21%
Mar 31, 2025
D. E. Shaw & Co., L.P.
3.79M
1.98%
+361.80K
+10.55%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
0.94%
Invesco NASDAQ Future Gen 200 ETF
0.5%
ARK Innovation ETF
0.23%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
iShares US Small-Cap Equity Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
View more
ARK Genomic Revolution ETF
Proportion0.94%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.5%
ARK Innovation ETF
Proportion0.23%
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.04%
iShares US Small-Cap Equity Factor ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
